Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil - Wikidata - wikimedia - TriplyDB

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

http://www.wikidata.org/entity/Q33958533

about

Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease.Antioxidant-mediated effects in a gerbil model of iron overload Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.Cardiac iron across different transfusion-dependent diseases.Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.Calcium channels and iron uptake into the heart.Combined histological and hematological assessment of iron-induced organ damage in a gerbil model of iron overload Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management.Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart.Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.Radiation nephropathy is not mitigated by antagonists of oxidative stress Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia.Practical medical applications of quantitative MR relaxometry.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Establishment of secondary iron overloaded mouse model: evaluation of cardiac function and analysis according to iron concentration.Iron chelation therapy in low risk myelodysplastic syndrome.Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.Update on the use of deferasirox in the management of iron overload.Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].Long-term efficacy of deferasirox in preventing cardiovascular complications in the iron-overloaded gerbil.Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

P2860

Q33670385-4BBBAF28-6286-4E1F-886A-072340402B27 Q33909024-1B5B4CB3-5D5A-4413-9BA2-06D34D94986C Q33909056-0F71300E-2FF4-4F08-A87C-55FDE86BFA6D Q33944090-C836E97A-4AD4-445F-B3AA-2CFA9594F70B Q33944180-8FD257FD-A88E-45C0-95E8-2BC1DE546E6B Q33958560-705280F4-C3F7-4081-A503-5AB167EF055D Q34692473-49187415-2B45-4C46-BDF1-7802A9C8E979 Q35172888-9283085D-4B31-42FA-BE28-327AE335D52D Q35440224-D8ED10B7-5EEA-4395-9296-12402900C150 Q36080315-1FD35450-38E4-411C-B5A4-8E78A5F8CB06 Q36477489-551A2483-B8C3-4984-839D-B36BCE3F7820 Q36851507-DC442722-F2A3-40C0-B86D-8104A4AE6FD3 Q37084711-B05E93DE-836F-4972-AA1D-A89767A52FC9 Q37307891-FF73AA7B-DA84-40A3-AEC4-3E404D9A669E Q37692645-4C10CAA7-2E44-4771-9AEC-AB7EC56D4DF3 Q38044345-5E6586FD-3343-4083-AEDC-C2133C6C3D41 Q38219588-A977A08A-45F2-4DE2-B824-4C569FA031BA Q38473461-51525EA5-A987-4DED-9539-37B327F3587E Q38903926-E9BCEF75-98B9-414B-BFE6-13A402B6CD70 Q38962101-76296409-EDAE-49C4-B2A8-2691BB637A01 Q40896307-AFC53B7A-2108-4750-BC6A-344F3B0A6C51 Q42117340-73E6BC60-2E92-414C-8357-FF4B4C1EA414 Q46209130-4E8B917C-0286-43B5-A998-2CFE67E82253 Q50277574-C284FB9A-5D93-48DF-A248-81962FB92252 Q57998367-A474FD92-F36B-42C1-9875-B68EA8950691

P2860

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

http://www.wikidata.org/entity/Q33958533

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

@ast

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

@en

type

label

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

@ast

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

@en

prefLabel

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

@ast

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

@en

P1433

Q33958533-8F9FC7AD-862E-4E88-AAD6-ABE920B73235

P1476

Q33958533-11FC1979-97B6-4030-BC29-69F72037B9DE

P2093

Q33958533-00FF1B74-39ED-4734-B493-B9429563FB7D

Q33958533-0E472F20-6A53-4EFF-8F77-A9CD59F01497

Q33958533-44242578-1D74-4396-8E2F-0DD11A138654

Q33958533-613FB02F-6664-442E-91DE-622675D6447F

Q33958533-794B0925-886C-4B15-BC5D-42E9F682EA79

Q33958533-C239DD06-7EED-4898-9503-392F5866CE67

Q33958533-C9D1CB3D-58EF-48B7-82DB-C00DA5CD98DC

Q33958533-D913BB7B-FCCB-4368-AE1F-10871BB93E7C

P2860

Q33958533-0536EFE7-D0CB-4C51-8411-71CEB87129ED

Q33958533-05B77409-DD6A-4C2F-B161-52F98F80DA6F

Q33958533-10A4EAAB-7762-4927-91E0-50DBC402B1F4

Q33958533-13705E65-2A3F-4D7C-A3D9-6850F47A591A

Q33958533-20EE04E3-4532-44B3-9FA6-B0BD2B4A3321

Q33958533-3902C173-097D-44C5-8308-C11981843968

Q33958533-3BAB2058-B097-4142-AC35-1AD2F2225027

Q33958533-402E0149-B9E6-40C3-9ACC-D07108916021

Q33958533-466CFCD1-6155-4FAB-9DCF-30685E48E0E4

Q33958533-523C0763-8D4A-4E91-A155-523E8E6252ED

P304

Q33958533-EC5AB6BB-5D84-4132-9D60-95D19C76BBF2

P31

Q33958533-BACE89CC-EB4A-4E0E-A38B-BBF971B84905

P356

Q33958533-F08428DD-E22B-4AB7-8ADD-AC4B67D9E955

P433

Q33958533-33E76053-3368-476C-B340-2DAD7539C710

P478

Q33958533-929C140F-7CA8-4BCA-BE0F-28F6F863C503

P577

Q33958533-E46191EF-BC4D-49C4-A23C-656F57B6F5FE

P5875

Q33958533-C3D4FD5A-4A08-4DD9-ACEA-5DB67AAD1ED5

P698

Q33958533-D56FB9CB-AABE-4D88-96D5-A2E00D60EBDA

P932

Q33958533-79734C20-2F4F-420A-B3AD-1ABD7BAA1A5C

P356

J.TRSL.2006.05.005

P1433

Translational Research

P1476

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

@en

P2093

Hanspeter Nick

http://www.w3.org/2001/XMLSchema#string

Hiro Shimada

http://www.w3.org/2001/XMLSchema#string

Ignacio Gonzalez

http://www.w3.org/2001/XMLSchema#string

John C Wood

http://www.w3.org/2001/XMLSchema#string

Marvin Nelson

http://www.w3.org/2001/XMLSchema#string

Maya Otto-Duessel

http://www.w3.org/2001/XMLSchema#string

Michelle I Aguilar

http://www.w3.org/2001/XMLSchema#string

Rex Moats

http://www.w3.org/2001/XMLSchema#string

P2860

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.

Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).

Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy.

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.

Iron-chelating therapy and the treatment of thalassemia.

The cardiac ryanodine receptor (calcium release channel): emerging role in heart failure and arrhythmia pathogenesis.

Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.

LPI-labile plasma iron in iron overload.

Results of long-term iron-chelating therapy.

P304

272-280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRSL.2006.05.005

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

148

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6652702

http://www.w3.org/2001/XMLSchema#string

P698

17145573

http://www.w3.org/2001/XMLSchema#string

P932

2896322

http://www.w3.org/2001/XMLSchema#string